A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy

Phase 2 Withdrawn Agios Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the effect of mitapivat on albumin creatinine ratio (ACR) response in participants with sickle cell disease (SCD) and nephropathy.

Timeline

Start: 2026-03
Primary completion: 2027-05
Completion: 2028-12

Outcome

Outcome not reported

Stopped (Enrollment): “Withdrawn prior to study start per sponsor decision. No patients were enrolled.”

Publications

Abbasi M, Srivastava A, Saraf SL. Management of Kidney Disease with Sickle Cell Disease. J Am Soc Nephrol. 2025 Oct 1;36(10):2041-2054. doi: 10.1681/ASN.0000000804. Epub 2025 Jun 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mitapivat	Small molecule	100 mg	Oral